The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors.
The effects of the endocannabinoid anandamide (arachidonylethanolamide, AEA) on the function of alpha4beta2 nicotinic acetylcholine receptors (nAChR) stably expressed in SH-EP1 cells were investigated using the whole-cell patch-clamp technique. In the concentration range of 200 nM to 2 microM, AEA significantly reduced the maximal amplitudes and increased the desensitization of acetylcholine (ACh)-induced currents. The effects of AEA could be neither replicated by the exogenous cannabinoid Delta(9)-tetrahydrocannabinol (1 microM) nor reversed by the selective CB1 receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (SR-141716A) (1 microM). The actions of AEA were apparent when applied extracellularly but not during intracellular dialysis. Furthermore, the effects of AEA ACh currents were not altered by the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid. The onset and washout of the AEA effects required several minutes (10-30 min), but the latter was significantly decreased in the presence of lipid-free bovine serum albumin (BSA). Moreover, BSA alone increased peak ACh current amplitudes and diminished desensitization rates in naive cells, suggesting a tonic modulation of alpha4beta2 nAChR function by an endogenous AEA-like lipid. Further analysis of AEA effects on alpha4beta2 nAChR-mediated currents, using a two-stage desensitization model, indicated that the first forward rate constant leading to desensitization, k(1), increased nearly 30-fold as a linear function of the AEA concentration. In contrast, the observation that the other three rate constants were unaltered by AEA suggested that AEA raised the energy of the activated state. These results indicate that AEA directly inhibits the function of alpha4beta2 nAChRs in a CB1 receptor-independent manner.
Spivak
Charles E
CE
National Institute on Drug Abuse, Intramural Research Program, Cellular Neurobiology Branch, Electrophysiology Unit, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. cspivak@intra.nida.nih.gov
Lupica
Carl R
CR
Oz
Murat
M
D000109:Acetylcholine / Q000494:pharmacology; D001095:Arachidonic Acids / Q000494:pharmacology*; D002460:Cell Line; D063388:Endocannabinoids; D006801:Humans; D007700:Kinetics; D018408:Patch-Clamp Techniques; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000502:physiology; D000077285:Rimonabant; D012710:Serum Albumin, Bovine / Q000378:metabolism
D001095:Arachidonic Acids; D063388:Endocannabinoids; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; D012710:Serum Albumin, Bovine; D000109:Acetylcholine; D000077285:Rimonabant; C078814:anandamide